Insights & Resources

Blocker entities can help fund managers attract tax-exempt and non-U.S. investors, preserve tax profiles and navigate financial and tax reporting.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Understand how the TCJA’s suspension of miscellaneous deductions impacts the deductibility of portfolio expenses for fund managers and investors.

First-time fund managers face complex compensation and tax challenges in an LLC or LP, with key considerations necessary when approaching personal income.

Navigating the tax implications of pass-through entity investments is crucial for fund managers. Our professionals can guide you through the complexities.

Unravel life sciences industry complexities, and discover the differences between FDA special review designations like Fast Track, Priority Review and Breakthrough.

Whether preceding an M&A transaction or another executive hire, due diligence identifies any red flags before inking a high-stakes deal.

The credit is aimed at bolstering and incentivizing the emerging biotechnology sector to create jobs and invest in NYC and is available 1/1/23-1/1/26.

Change Healthcare was impacted by a cybersecurity incident that breached its information technology network.

In a business sale, due diligence is critical to mitigate the risk of unexpected tax issues for buyers and sellers. Find out key components of tax due diligence.

A summary of changes to R&E expenditure tax treatment in the proposed Tax Relief for American Families and Workers Act of 2024.

Administrative, physical, and technical safeguards are an essential element of HIPAA security and essential for protecting PHI and ePHI.